Gregory Sargen - 15 Jun 2026 Form 4 Insider Report for Protara Therapeutics, Inc. (TARA)

Reporting relationship: Director
Issuer ticker: TARA
Reported as of: 15 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2026, 16:05:18 UTC
Prior SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Mary Grendell, Attorney-in-fact

Key filing fact

Gregory Sargen filed Form 4 for Protara Therapeutics, Inc. (TARA) on 16 Jun 2026.

Key facts

This page summarizes Gregory Sargen's Form 4 filing for Protara Therapeutics, Inc. (TARA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2026, 16:05.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001227835 Primary reporting owner

SARGEN GREGORY

Relationship: Director
Address: C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK
Signature: /s/ Mary Grendell, Attorney-in-fact
Signature date: 16 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +31,000
Change %
Price: $0.000000^*
Shares after: 31,000
Date: 15 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 31,000
Exercise price: $3.94
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.